Valbenazine Tosylate
Brand name: Ingrezza
Rank #34 of 500 drugs by total cost
$553.8M
Total Cost
73,914
Total Claims
$553.8M
Total Cost
3,217
Prescribers
$7,493
Cost per Claim
1,112
Beneficiaries
74,315
30-Day Fills
$172K
Avg Cost/Provider
23
Avg Claims/Provider
About Valbenazine Tosylate
Valbenazine Tosylate (sold as Ingrezza) was prescribed 73,914 times by 3,217 Medicare Part D providers in 2023, costing the program $553.8M. At $7,493 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 31 | Pomalidomide (Pomalyst) | $589.0M | 27,253 |
| 32 | Lipase/Protease/Amylase (Zenpep) | $577.7M | 321,809 |
| 33 | Insulin Degludec (Tresiba Flextouch U-100) | $567.8M | 597,178 |
| 34 | Valbenazine Tosylate (Ingrezza) | $553.8M | 73,914 |
| 35 | Fluticasone Propion/Salmeterol (Advair Diskus) | $523.2M | 1,289,942 |
| 36 | Varicella-Zoster Ge/As01b/Pf (Shingrix) | $514.4M | 2,419,884 |
| 37 | Tafamidis (Vyndamax) | $511.1M | 20,589 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology